Market Overview

UPDATE: Cantor Fitzgerald Raises PT on Ligand Pharmaceuticals on Announced Spectrum Partnership

Related LGND
Hedge Fund Guru Emmanuel Lemelson Just Revealed How He's Trading Apple (And 3 Other Stocks)
Lemelson Capital Management CIO Discusses Ligand Pharmaceuticals Prior To Company Issuing Weak Guidance

In a report published Monday, Cantor Fitzgerald analyst Irina Rivkind reiterated a Hold rating on Ligand Pharmaceuticals (NASDAQ: LGND), and raised the price target from $23.00 to $26.00.

In the report, Rivkind noted, “On March 14 the company announced its license and global supply agreement with Spectrum Pharmaceuticals on Captisol-enabled Melphalan for the treatment of multiple myeloma. Ligand received a $3M upfront payment and negotiated a healthy double-digit royalty (we estimate 20%) in addition to $50M in milestones that will be based on multiple regulatory and commercial events such as NDA acceptance, FDA approval, and launch. Spectrum is also taking over development costs, effective immediately.”

Ligand Pharmaceuticals closed on Friday at $23.27.

Latest Ratings for LGND

DateFirmActionFromTo
Jul 2014Empire Asset ManagementInitiates Coverage onSell
Mar 2014Brinson PatrickInitiates Coverage onOutperform
Feb 2014McNicoll Lewis VlakMaintainsBuy

View More Analyst Ratings for LGND
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Analyst Ratings

 

Related Articles (LGND)

Around the Web, We're Loving...

Get Benzinga's Newsletters